{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    8,
    13,
    30,
    42,
    57
  ],
  "modelUsed": "gemini-3-flash",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to study procedures listed in the Schedule of Activities"
      },
      {
        "id": "ref_2",
        "name": "Concomitant Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.7",
        "sectionTitle": "Concomitant Therapy",
        "description": "Reference to prohibited medications list"
      },
      {
        "id": "ref_3",
        "name": "Pharmacokinetics Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "Reference to PK sample collection details"
      },
      {
        "id": "ref_4",
        "name": "Hyperglycemia Thresholds Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2.1.2",
        "sectionTitle": "Insulin Glargine",
        "description": "Reference to prespecified thresholds for rescue therapy"
      },
      {
        "id": "ref_5",
        "name": "Hyperglycemia Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2.2",
        "sectionTitle": "Severe, Persistent Hyperglycemia",
        "description": "Reference to rescue therapy protocols"
      },
      {
        "id": "ref_6",
        "name": "Study Governance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Study Governance Considerations",
        "description": "Reference to detailed study governance descriptions"
      },
      {
        "id": "ref_7",
        "name": "Hypoglycemia Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2.1",
        "sectionTitle": "Hypoglycemia",
        "description": "Reference for further information on hypoglycemia management"
      },
      {
        "id": "ref_8",
        "name": "Hepatic Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4.5.1",
        "sectionTitle": "Hepatic Safety Monitoring",
        "description": "Reference for liver marker elevation protocols"
      },
      {
        "id": "ref_9",
        "name": "Hepatic Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-Emergent Abnormality",
        "description": "Reference for hepatic monitoring tests"
      },
      {
        "id": "ref_10",
        "name": "GI Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.7.1",
        "sectionTitle": "Management of Patients with Gastrointestinal Symptoms",
        "description": "Reference for management of severe GI adverse events"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "For those patients whose participation in this study is affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)... please refer to Appendix 8 for additional instructions.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "2. Schedule of Activities",
        "pageNumber": 14
      },
      {
        "id": "annot_3",
        "text": "56 mg/dL",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "7.4.2 Reduction and/or Discontinuation of Concomitant Antihyperglycemic Medications",
        "pageNumber": 43
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8F-MC-GPGM",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-07-18",
        "description": "Protocol Electronically Signed and Approved by Lilly",
        "amendmentNumber": "Original"
      },
      {
        "id": "ver_2",
        "versionNumber": "I8F-MC-GPGM(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-09-28",
        "description": "Amendment (a) Electronically Signed and Approved by Lilly",
        "amendmentNumber": "Amendment (a)"
      },
      {
        "id": "ver_3",
        "versionNumber": "I8F-MC-GPGM(b)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-07-10",
        "description": "Amendment (b) incorporating SURPASS-4 study details and COVID-19 instructions",
        "amendmentNumber": "Amendment (b)"
      }
    ],
    "summary": {
      "referenceCount": 10,
      "annotationCount": 3,
      "versionCount": 3
    }
  }
}